Story 75

Clinical trials lead to new treatment

We are on a mission to support innovative, groundbreaking research that can result in improved treatments and better outcomes for cancer patients. In 1980, the Canadian Cancer Society began funding the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, an organization that is dedicated to carrying out high-level clinical research into new cancer treatments, preventive therapies and better diagnostics. When researchers discover a new method or treatment that is safe and effective in clinical trials, then it can be made available to the public.

In this video, 4 sisters describe how they were inspired by their mother to participate in a clinical trial to test whether the drug exemestane reduces cancer incidence in women at high risk for the disease. Their mother died of breast cancer in 1983 and the sisters wanted to get involved in the trial so that others don't have to endure the pain their mother experienced at the end of her life. In 2011, the landmark trial found that the drug reduces the risk of breast cancer by 65% for women at increased risk for the disease.

Joe Pater, Director of the NCIC Clinical Trial Group, and Elizabeth Eisenhauer, Director of the CTG Investigational New Drug Program, at Queen's University, 1980s.

The Canadian Cancer Society funds more research into more types of cancer than any other national charity in Canada. Learn more about the exciting research we are currently funding.